Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Phesi launches AI-driven trial accelerator, saving $7m per t...

Yesterday, global provider of patient-centric data analytics, Phesi launched its AI-driven Trial Accelerator Platform, an

Oculis SA and EBAC join to drive ophthalmology innovation

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi

Report: Reinventing product and portfolio value for the biop...

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing ne

Practical advice for Early Scientific Advice (ESA) in HTA su...